Examkin

Soru

Zorluk: KolayPharmacokinetic and Pharmacodynamic Principles

Match each pharmacodynamic agent or modulator to its corresponding effect on the dose-response curve.

  • Competitive antagonist (added to a full agonist)Shifts the dose-response curve to the right (increases EC50) without altering maximal efficacy (Emax).
  • Noncompetitive antagonist (added to a full agonist)Shifts the dose-response curve downward (decreases Emax) without altering apparent potency (EC50).
  • Partial agonist (administered alone)Binds to the receptor but produces a lower maximal efficacy (Emax) even at full receptor occupancy.
  • Positive allosteric modulator (added to a full agonist)Shifts the dose-response curve to the left (decreases EC50) without altering maximal efficacy (Emax).

Cevap

Competitive antagonist increases EC50 (no change in Emax); Noncompetitive antagonist decreases Emax (no change in EC50); Partial agonist has a lower Emax at full occupancy; Positive allosteric modulator decreases EC50 (no change in Emax).
Each modulator uniquely alters the dose-response curve based on its binding site and intrinsic activity. Competitive antagonists affect potency (EC50), noncompetitive antagonists affect efficacy (Emax), partial agonists have inherently lower efficacy, and positive allosteric modulators increase potency (lower EC50).

Adım Adım Çözüm

1
Analyze the effect of a competitive antagonist on the dose-response curve.
It competes for the binding site but can be overcome by more agonist, shifting the curve right (increasing EC50) without changing Emax.
This establishes the relationship between reversible active-site binding and apparent potency.
2
Analyze the effect of a noncompetitive antagonist on the dose-response curve.
It binds irreversibly or allosterically, meaning excess agonist cannot overcome it. This shifts the curve downward (decreasing Emax) without altering the EC50 of the remaining available receptors.
This differentiates non-surmountable antagonism from surmountable (competitive) antagonism.
3
Analyze the characteristics of a partial agonist.
It has lower intrinsic efficacy, meaning the maximum possible response is lower (decreased Emax) compared to a full agonist, regardless of dose.
This tests the definition of intrinsic efficacy versus receptor affinity.
4
Analyze the effect of a positive allosteric modulator (PAM).
It enhances receptor affinity for the endogenous or exogenous agonist, shifting the curve left (decreasing EC50) while keeping Emax unchanged.
This demonstrates understanding of allosteric enhancement without direct activation.

Anahtar Kavram

Pharmacodynamic principles regarding receptor binding, encompassing efficacy (Emax) and potency (EC50) shifts due to various modulators.
Tahmini Süre:1m 0s
Bu soruyu puanla

Konular

Pharmacokinetic and Pharmacodynamic Principles

Bu konudan daha fazla soru